Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis
Open Access
- 1 August 2020
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 72 (8), 1350-1360
- https://doi.org/10.1002/art.41294
Abstract
Objective To assess the safety and efficacy of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc). Methods A randomized, double-blind, placebo-controlled, phaseIIstudy was conducted at 9SSc clinics in theUS. Adults with dcSSc of <= 6 years' duration who were receiving stable standard-of-care treatment were randomized to receive lenabasum (n = 27) or placebo (n = 15). Lenabasum doses were 5 mg once daily, 20 mg once daily, or 20 mg twice daily for 4 weeks, followed by 20 mg twice daily for 8 weeks. Safety and efficacy were assessed at weeks 4, 8, 12, and 16. Results Adverse events (AEs) occurred in 63% of the lenabasum group and 60% of the placebo group, with no seriousAEs related to lenabasum. Compared to placebo, lenabasum treatment was associated with greater improvement in the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score and other efficacy outcome measures that assessed overall disease, skin involvement, and patient-reported function. The medianCRISSscore increased in the lenabasum group during the study, reaching 0.33, versus 0.00 in the placebo group, at week 16 (P= 0.07 by 2-sided mixed-effects model repeated-measures analysis). Gene expression in inflammation and fibrosis pathways was reduced, and inflammation and fibrosis were improved on histologic evaluation of skin biopsy specimens, in the lenabasum group compared to the placebo group (allP <= 0.05). Conclusion Despite a short trial duration in a small number of patients in this phaseIIstudy in dcSSc, our findings indicate that lenabasum improves efficacy outcomes and underlying disease pathology with a favorable safety profile.This publication has 49 references indexed in Scilit:
- The Cannabinoid Receptor type 2 Q63R variant increases the risk of celiac disease: Implication for a novel molecular biomarker and future therapeutic interventionPharmacological Research, 2012
- g:Profiler—a web server for functional interpretation of gene lists (2011 update)Nucleic Acids Research, 2011
- Targeting the Cannabinoid Pathway Limits the Development of Fibrosis and Autoimmunity in a Mouse Model of Systemic SclerosisThe American Journal of Pathology, 2010
- The 5-D itch scale: a new measure of pruritusBritish Journal of Dermatology, 2009
- Innate immunity and inflammation in systemic sclerosisCurrent Opinion in Rheumatology, 2009
- Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblastsRheumatology, 2009
- The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion‐induced cardiomyopathyThe FASEB Journal, 2009
- Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Cannabinoid signallingLife Sciences, 2006
- Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosisArthritis & Rheumatism, 1999